ISAL 2017 | Challenges with measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele, MD, PhD of VU University Medical Center, Amsterdam, Netherlands discusses the challenges of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML). Prof. Ossenkoppele explains that a lot of experience is needed to perform a MRD assessment, i.e. experienced labs need to perform the tests. The European Leukemia Net is working on recommendations and guidelines on how to apply molecular MRD and flow cytometric MRD in order to harmonize the process.
Recorded at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany.
Get great new content delivered to your inboxSign up